SS18-SSX Antilichaam/eiwit SSXT

S18 is a protein that has been shown to be a part of the SWI/SNF complex. The SS18-SSX fusion proteins are a result of in-frame fusions that fuse the SS18 gene on chromosome 18 with X chromosome genes SSX1, SSX2, and to a lesser extent SSX4. Human synovial sarcoma (SS) accounts for 8-10% of all soft tissue malignancies and 95% of these malignancies express the recurrent translocation of the SS18 gene on chromosome 18. The N-terminal SNH domain (SYT N-terminal homology domain) of the SS18 protein interacts with SWI/SNF chromatin remodeling complexes via the N terminal region of BRM and BRG1 subunits. Studies of the SS18-SSX fusion in SS suggest that endogenous SS18 competes with the mutant SS18-SSX fusion for occupancy in the SWI/SNF complexes resulting in the displacement of SNF5 (BAF47) subunit. Displacement of the SNF5 subunit results in altered function of the SWI/SNF complex that leads to deregulated expression of genes such as Sox2 in synovial sarcoma.

Immunohistochemistry (FFPE) : 1-2 µg/mL, Western blot: 2-4 µg/mL

Q15532

Human

A recombinant fragment corresponding to the fusion site of human SS18-SSX protein was used as the immunogen for the SS18-SSX antibody.

SS18.SSX/12628R

IHC-P, WB

Protein A affinity

Purified

This SS18-SSX antibody is available for research use only.

Aliquot the SS18-SSX antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05% sodium azide

Optimal dilution of the SS18-SSX antibody should be determined by the researcher.

Nucleus